secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001628280-24-046583
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings
--------------------------------------------------------------------------

- Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.
- Closed $30M debt and $35M equity financings in Q3, extending cash runway into 1Q2026.
- Total operating expenses $14.4M (R&D $8.1M, G&A $6.3M) vs $16.1M in Q3 2023.
- OCU400 Phase 3 liMeliGhT trial for RP on track to complete enrollment in 1H2025.
- OCU410 Phase 2 recruiting; OCU410ST DSMB approved Phase 2; OCU200 IND cleared for Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/0001628280-24-046583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/ocgn-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer